Contaminated heparin associated with adverse clinical events and activation of the contact system

New England Journal of Medicine

Volumn 358, Issue 23, 2008, Pages 2457-2467

  Kishimoto, Takashi Kei ^a   Viswanathan, Karthik ^b   Ganguly, Tanmoy ^a   Elankumaran, Subbiah ^c   Smith, Sean ^a   Pelzer, Kevin ^c   Lansing, Jonathan C ^a   Sriranganathan, Nammalwar ^c   Zhao, Ganlin ^a   Galcheva Gargova, Zoya ^a   Al Hakim, Ali ^d   Bailey, Gregory Scott ^a   Fraser, Blair ^d   Roy, Sucharita ^a   Rogers Cotrone, Thomas ^c   Buhse, Lucinda ^d   Whary, Mark ^a   Fox, James ^a   Nasr, Moheb ^d   Dal Pan, Gerald J ^d   Shriver, Zachary ^a,b   Langer, Robert S ^b   Venkataraman, Ganesh ^a,b   Austen, K Frank ^e   Woodcock, Janet ^d   Sasisekharan, Ram ^b,f   more..

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Koch Institute for Integrative Cancer Research   (United States)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; CHONDROITIN SULFATE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; DERMATAN SULFATE; DEXTRAN SULFATE; HEPARIN;

ADULT; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG SCREENING; FEMALE; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KALLIKREIN KININ SYSTEM; LOADING DRUG DOSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SWINE;

EID: 44849115945     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0803200     Document Type: Article

References (20)

1. Acute allergic-type reactions among patients undergoing hemodialysis - multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008;57:124-5.
2. Information on adverse event reports and heparin. Rockville, MD: Food and Drug Administration, 2008. (Accessed May 12, 2008, at http://www.fda.gov/cder/ drug/infopage/heparin/adverse_events.htm.)
3. Information on heparin sodium injection. Rockville, MD: Food and Drug Administration, 2008. (Accessed May 12, 2008, at http://www.fda.gov/cder/drug/ infopage/heparin/default.htm#screening.)
4. Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a major contaminant in heparin associated with adverse clinical events. Nat Biotechnol (in press).
5. Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984;63:1453-9.
6. Henry SP, Giclas PC, Leeds J, et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997;281:810-6.
7. Silverberg M, Diehl SV. The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate: the effect of the Mr of the activating polyanion. Biochem J 1987;248:715-20.
8. Baxter provides update on the heparin investigation. Deerfield, IL: Baxter, March 19, 2008. (Accessed May 12, 2008, at http://www.baxter.com/ products/biopharmaceuticals/downloads/heparin_03-19-08.pdf.)
9. Silverberg M, Dunn JT, Garen L, Kaplan AP. Autoactivation of human Hageman factor: demonstration utilizing a synthetic substrate. J Biol Chem 1980;255:7281-6.
10. Verhamme IM, Bock PE, Jackson CM. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem 2004;279:9785-95.
11. Stead N, Kaplan AP, Rosenberg RD. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976;251:6481-8.
12. Olson ST, Sheffer R, Francis AM. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein. Biochemistry 1993;32:12136-47.
13. Pixley RA, Cassello A, De La Cadena RA, Kaufman N, Colman RW. Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost 1991;66:540-7.
14. Kaplan AP, Austen KF. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971;133:696-712.
15. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981;153:665-76.
16. DiScipio RG. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982;45:587-95.
17. Wiggins RC, Giclas PC, Henson PM. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 1981;153:1391-404.
18. Schaiff WT, Eisenberg PR. Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis 1997;8:9-18.
19. Wiggins RC. A different cleavage site for high molecular weight kininogen in vivo following intravenous injection of dextran sulfate in the rabbit. Circ Res 1986;58:595-604.
20. Siebeck M, Cheronis JC, Fink E, et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 1994;77:2675-80.